Capital Securities released a research report on April 22 stating that it gave Tianshili (600535.SH) a purchase rating. The main reasons for the rating include: 1) the performance of traditional Chinese medicine is stable, the negative effects of chemical drug collection are fully reflected, and it is expected to reach an inflection point after the approval of new indications for biopharmaceuticals; 2) the pipeline of innovative traditional Chinese medicines continues to be rich and is about to enter a revenue period. (Mainichi Keizai Shimbun)
首创证券4月22日发布研报称，给予天士力（600535.SH）买入评级。评级理由主要包括：1）中药表现平稳，化学药集采负面影响已充分体现，生物药新适应症获批后有望迎来拐点；2）中药创新药管线持续丰富，即将进入收入期。（每日经济新闻）
Capital Securities released a research report on April 22 stating that it gave Tianshili (600535.SH) a purchase rating. The main reasons for the rating include: 1) the performance of traditional Chinese medicine is stable, the negative effects of chemical
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.